• Catalpol as a Neuroimmune Modulator: Mechanistic Depth for T

  2026-05-16

  Explore how Catalpol, a natural iridoid glycoside, uniquely modulates neuroimmune and inflammatory pathways in translational models. This cornerstone article reveals mechanistic details and experimental guidance distinct from prior neuroprotection and osteoporosis research.

• DAPI Solution (1 mg/mL): Verifiable Protocols and Biological

  2026-05-15

  DAPI Solution (1 mg/mL) is a validated, blue-fluorescent nuclear staining dye for DNA detection in fixed, apoptotic, or dead cells. It offers robust nuclear visualization and facilitates viability assessment, with protocols and applications supported by peer-reviewed evidence and manufacturer data. APExBIO provides this solution in a standardized DMSO stock format for reproducible research workflows.

• Rotigotine's Modulation of Bladder Function in PD Rat Models

  2026-05-15

  This study elucidates how Rotigotine, a dopamine D1/D2-like agonist, directly modulates lower urinary tract function in a rat model of Parkinson’s disease (PD). The findings highlight dose- and route-dependent effects on bladder overactivity, suggesting new avenues for addressing non-motor PD symptoms.

• NBC19: Redefining NLRP3 Inflammasome Inhibition in Translati

  2026-05-14

  This thought-leadership article explores the mechanistic and translational value of NBC19, a nanomolar NLRP3 inflammasome inhibitor, for inflammation research. It connects recent discoveries on metabolic regulation of macrophage-driven cytokine release—specifically HMGB1 secretion via lactate signaling—to the precision and reproducibility offered by NBC19. The piece provides protocol guidance, compares NBC19 with existing tools, and offers strategic insights for translational researchers aiming to bridge preclinical findings with clinical endpoints.

• Nose-to-Brain Rotigotine Nanoparticles: Neuroprotection in P

  2026-05-14

  This study demonstrates that intranasal delivery of rotigotine-loaded chitosan nanoparticles facilitates efficient nose-to-brain targeting, enhancing bioavailability and neuroprotective effects in both SH-SY5Y cells and a rat model of Parkinson’s disease. These findings highlight a promising nanotechnology-based approach for improving antiparkinsonian therapy and suggest new avenues for translational research.

• Rotigotine Hydrochloride: Translational Insights Beyond Dopa

  2026-05-13

  Explore the multifaceted potential of Rotigotine hydrochloride as a dopamine D2/D3 receptor agonist, highlighting its neuroprotective, antidepressant, and experimental versatility. This in-depth analysis reveals overlooked assay strategies and translational nuances for advanced Parkinson's disease research.

• Lysoptosis: Evolutionary Cell Death Pathway Defined by Serpi

  2026-05-13

  This article explores the recent identification of lysoptosis as a distinct, evolutionarily conserved cell death pathway reliant on lysosomal membrane permeabilization and cathepsin release, revealed through serpin knockout models. The findings clarify the unique molecular signature of lysoptosis versus other regulated cell death modalities, with practical implications for dissecting cysteine protease-mediated mechanisms in apoptosis and neurodegeneration research.

• GANT61 GLI Inhibitor: Advanced Protocols for Cancer Research

  2026-05-12

  GANT61 is a selective GLI inhibitor that empowers cancer researchers to dissect Hedgehog pathway signaling and overcome immunotherapy resistance. This guide translates cutting-edge findings into actionable protocols, highlighting troubleshooting insights for robust GLI-mediated transcription inhibition and tumor growth suppression.

• BX795: PDK1 Inhibition and Beyond for Translational Research

  2026-05-12

  This article explores BX795 as a multi-kinase inhibitor, highlighting its mechanistic impact on innate immunity and cancer signaling while offering strategic guidance for translational researchers. Drawing on recent findings—including the role of TBK1 in HBV immune evasion—we provide evidence-based insights, protocol parameters, and a critical perspective on BX795’s unique position in the landscape of PI3K/Akt/mTOR and innate immune pathway modulation.

• PLK1-Mediated Phosphorylation of p31comet Regulates Mitotic

  2026-05-11

  This study elucidates how Polo-like kinase 1 (PLK1) phosphorylates p31comet to control the disassembly of mitotic checkpoint complexes (MCCs), offering mechanistic insight into cell cycle regulation. The findings advance our understanding of mitotic checkpoint inactivation and suggest new avenues for targeting PLK1 in cancer research.

• Veratridine in Neurotoxicity Modeling: Mechanisms, Assay Des

  2026-05-11

  Explore how Veratridine, a voltage-gated sodium channel opener, enables precise modeling of excitotoxicity and neuronal injury. This article uniquely dissects mechanistic insights and assay optimization strategies, advancing sodium channel dynamics research beyond existing guides.

• Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO): Proto

  2026-05-10

  The Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) safeguards proteins during extraction by inhibiting a broad range of proteases without interfering with divalent cation-dependent assays. This product is essential for workflows like Western blotting, co-immunoprecipitation, and kinase assays, but should not be used where EDTA-based inhibition is specifically required.

• Saracatinib Blocks Necroptosis via MLKL Targeting in Psoriat

  2026-05-09

  This study identifies saracatinib as a novel inhibitor of necroptosis, acting through direct targeting of MLKL to suppress inflammatory cell death and ameliorate psoriatic skin inflammation. The findings suggest new avenues for drug repositioning and mechanistic screening in inflammatory and cell death-related diseases.

• Cyclo (-RGDfC) (SKU A8790): Data-Driven Solutions in Cell As

  2026-05-09

  This article delivers scenario-based, evidence-backed guidance for biomedical researchers using Cyclo (-RGDfC) (SKU A8790) in cell viability, proliferation, and cytotoxicity assays. We address real laboratory challenges—such as integrin specificity, peptide stability, and data reproducibility—demonstrating how Cyclo (-RGDfC) from APExBIO enables robust, high-fidelity experimental workflows.

• Ibrexafungerp Retains Antifungal Activity at Vaginal pH in V

  2026-05-08

  This study demonstrates that ibrexafungerp (MK 3118) maintains potent in vitro activity against both fluconazole-susceptible and -resistant vaginal Candida isolates at acidic pH, a condition that typically reduces efficacy of standard antifungals. These findings highlight ibrexafungerp’s translational relevance for treating vulvovaginal candidiasis, particularly in azole-resistant contexts.

452 records 18/31 page Previous Next First page 上5页 1617181920 下5页 Last page